Evidence map›Paper›PMID 40257669›Full record

ReviewCurrent treatment options in oncology2025

Cardio-Oncology and Breast Cancer Therapies.

Rohit Singh, Krina Patel, Haze Xu, Aderonke Adeniyi, Jenica N Upshaw, Peter Van Buren, Peter A Kaufman, Kim Dittus, Kara K Landry

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rohit SinghDivision of Hematology/Oncology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA.
Krina PatelDivision of Cardiology, Department of Medicine, Tufts Medical Center, Boston, MA, USA.
Haze XuDivision of Hematology/Oncology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA.
Aderonke AdeniyiDivision of Cardiology, Department of Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA.
Jenica N UpshawDivision of Cardiology, Department of Medicine, Tufts Medical Center, Boston, MA, USA.
Peter Van BurenDivision of Cardiology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA.
Peter A KaufmanDivision of Hematology/Oncology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA.
Kim DittusDivision of Hematology/Oncology, Department of Medicine, University of Wisconsin, Madison, WI, USA.
Kara K LandryDivision of Hematology/Oncology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA. kara.landry@med.uvm.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementAssessing cardiac risk prior to initiating breast cancer treatment, monitoring cardiac function during treatment, and implementing appropriate follow-up strategies are essential components of managing cardiotoxicity in breast cancer patients. A comprehensive cardiovascular evaluation should be conducted before treatment, including a detailed medical history, physical examination, and baseline cardiac imaging. Risk stratification tools can aid in determining the individual patient's risk profile. Close monitoring of cardiac function, including regular assessment of left ventricular ejection fraction (LVEF) and monitoring for signs and symptoms of cardiac dysfunction, is crucial during treatment. Prompt action should be taken if an adverse cardiovascular event is detected, including considering discontinuing or modifying the treatment regimen. Appropriate follow-up care is essential to monitor for long-term cardiac effects and optimize cardiovascular health in breast cancer survivors. Regular cardiovascular assessments, lifestyle modifications, and collaboration between healthcare professionals are important in managing cardiotoxicity effectively.

Indexed as

Antineoplastic AgentsBreast NeoplasmsCardiovascular DiseasesCardio-OncologyCardiotoxicityDisease ManagementFemaleHumansRisk FactorsAntineoplastic AgentsBreast cancerCardio-oncologyCardiotoxicity

Identifiers

PMID40257669

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.